Overview
- Editors:
-
-
Kevin J. Scanlon
-
Berlex Biosciences, Richmond
Access this book
Other ways to access
About this book
The purpose of Applications Therapeutic of Ribozymes is to provide an overview of the utility of ribozymes to selectively inhibit the expression of RNA. The ribozyme applications appearing in this book should benefit not only those experienced in ribozymes, but also those applying this ribozyme technology for the first time. It is hoped that a better understanding of the therapeutic application ofribozymes will have a significant impact on human disease in the near future. The field ofribozyme biochemistry has come a long way since the initial observation that RNA is capable of catalysis, initially in cis during processing of larger molecules and ultimately the use of ribozymes in trans to achieve cleavage of target sequence. The fundamental observation that hammerhead (and subsequently hairpin) ribozymes could be designed to cleave a target messenger RNA, and the clarification of sequence restrictions in both the ribozyme and the target RNA, have paved the ways for the use of ribozymes as a tool to manipulate gene expression at the molecular level. This had pre- ously been a domain of antisense oligonucleotides and triplex DNA. Sub- quent studies have explored the myriad biological systems in which ribozyme-mediated inhibition of genes involved in various cellular processes may be used to uncouple important signaling pathways or to reverse the p- notypic expression of a pathologic process.
Similar content being viewed by others
Article
Open access
27 June 2017
Article
08 September 2022
Table of contents (29 protocols)
-
-
- Philip Hendry, Trevor J. Lockett, Maxine J. McCall
Pages 1-15
-
-
-
- Lun-Quan Sun, Wayne Gerlach, Geoff Symonds
Pages 51-64
-
- Eric M. Poeschla, Mang Yu, Mark C. Leavitt, Flossie Wong-Staal
Pages 65-82
-
- Jun Ohkawa, Yutaka Takebe, Kazunari Taira
Pages 83-95
-
- Gerd Hobom, Annette Menke
Pages 97-110
-
- Fritz von Weizsäcker, Hubert E. Blum, Jack R. Wands
Pages 111-117
-
-
-
- Akira Irie, ierry Tsai, Mohammed Kashani-Sabet
Pages 153-168
-
- Tsukasa Ohkawa, Mohammed Kashani-Sabet
Pages 169-192
-
- Hiroshi Kijima, David Y. Bouffard, Kevin J. Scanlon
Pages 193-208
-
- Alex W. Tong, Yu-An Zhang, John Nemunaitis, Gabriele Mues
Pages 209-222
-
- Toshiya Suzuki, Lisa D. Curcio, Jerry Tsai, Mohammed Kashani-Sabet
Pages 223-239
-
- Gunhild M. Mælandsmo, Inge Kjønniksen, Eivind Hovig, Kevin J. Scanlon, Øystein Fodstad
Pages 241-260
-
-
- Lance H. Leopold, Scott K. Shore, Ramana M. V. Reddy, E. Premkumar Reddy
Pages 279-292
-
- Hiromichi Matsushita, Hiroyuki Kobayashi, Masahiro Kizaki, Yasuo Ikeda
Pages 293-310
Reviews
". . . an impressive collection of ribozyme applications. . .a useful investment for anyone who contemplates or is actively using ribozymes for target RNA inactivations."-Nature Medicine
Editors and Affiliations
-
Berlex Biosciences, Richmond
Kevin J. Scanlon